Skip to main content
ARIX BIOSCIENCE PLC logo

ARIX BIOSCIENCE PLC — Investor Relations & Filings

Ticker · ARIX ISIN · GB00BD045071 LEI · 213800OVT3AHQCXNIX43 IL Financial and insurance activities
Open in API
Filings indexed 547 across all filing types
Latest filing 2017-10-10 Regulatory Filings
Country GB United Kingdom
Listing IL ARIX

About ARIX BIOSCIENCE PLC

https://www.arixbioscience.com/

Arix Bioscience plc is a global venture capital company that specializes in the biotechnology and life sciences sectors. The firm's primary activity involves investing in and building innovative biotech companies, providing capital and strategic support from early stages, including seed, preclinical, and clinical development. Arix focuses on identifying and nurturing breakthrough advances in life sciences to accelerate the development of new medical technologies and therapies. According to public information, the company has entered into a process of liquidation.

Recent filings

Filing Released Lang Actions
Arix Bioscience notes positive data from Amplyx
Regulatory Filings Classification · 1% confidence The document is identified by the header 'RNS Number : 1301T' and concludes with 'This information is provided by RNS The company news service from the London Stock Exchange END'. This strongly indicates it is a regulatory announcement disseminated through the London Stock Exchange's Regulatory News Service (RNS). The content itself is an update noting positive clinical data from a subsidiary (Amplyx) regarding a drug candidate (APX001). Since this is a general regulatory announcement that doesn't fit the specific categories like Earnings Release (ER), Director's Dealing (DIRS), or Capital Update (CAP), the most appropriate classification is the general regulatory filing fallback category, RNS.
2017-10-10 English
Arix participates in $80 million Autolus financing
Share Issue/Capital Change Classification · 1% confidence The document is identified by the 'RNS Number : 7713R' header and the concluding statement 'This information is provided by RNS The company news service from the London Stock Exchange'. The content details Arix Bioscience's participation in a financing round for Autolus, which involves capital allocation and investment activity. This fits best under 'Capital/Financing Update' (CAP). Although it is an RNS announcement, the specific nature of the announcement (financing) makes CAP more precise than the general fallback RNS.
2017-09-26 English
Clinical progress from Autolus
Regulatory Filings Classification · 1% confidence The document is identified by the 'RNS Number : 9671Q' header and the concluding statement 'This information is provided by RNS The company news service from the London Stock Exchange'. The content is a brief announcement noting positive clinical study updates from an associated company (Autolus Limited). Since this is a general regulatory announcement that does not fit into specific categories like Earnings Release (ER), Director's Dealing (DIRS), or Capital Change (CAP), and it is clearly sourced from the London Stock Exchange's news service, the most appropriate classification is the general Regulatory Filings category (RNS). The document length (3787 chars) is short, but it is reporting news directly, not announcing the publication of a separate, larger report, thus RNS is preferred over RPA.
2017-09-18 English
Capital Markets Meeting Today
Report Publication Announcement Classification · 1% confidence The document is identified by the 'RNS Number : 9654Q' header, indicating it is a regulatory news service announcement from the London Stock Exchange. The content describes the company hosting a 'Capital Markets Meeting' for investors and analysts, detailing the schedule, presenters (CEO, Chairman, and CEOs of portfolio companies), and providing a link to a live webcast. This type of announcement, which informs the market about an upcoming investor/analyst event where strategy and progress will be discussed, aligns best with an Investor Presentation (IP) or a general regulatory announcement. Since it is an announcement about an event where presentations will be given, and it is distributed via RNS, it is a regulatory filing. However, given the specific nature of announcing a meeting focused on strategy and progress to investors, it is closely related to investor communication. Since there is no specific code for 'Investor/Analyst Event Announcement', and it is a formal regulatory release, 'RNS' (Regulatory Filings) is the most appropriate fallback, although 'IP' (Investor Presentation) is conceptually close if the content were the presentation itself. Given the structure as a news release announcing the event, RNS is the safest classification, or potentially 'RPA' if interpreted as announcing the availability of presentation materials (which are webcast). Given the focus on the event itself and the RNS header, I will classify it as RNS, as it is a general regulatory announcement.
2017-09-18 English
Arix Bioscience Capital Markets Meeting
Report Publication Announcement Classification · 1% confidence The document is a formal announcement disseminated via RNS (RNS Number : 6954Q) dated September 14, 2017. The content explicitly states that Arix Bioscience will host an 'inaugural Capital Markets Meeting for investors and analysts' on September 18, 2017, detailing the agenda, presenters (CEO, Chairman, and CEOs of Group Businesses), and logistics (location, time, webcast). This type of event, focused on providing strategy updates and progress to investors and analysts, aligns best with an Investor Presentation (IP) or a meeting designed to present company information. Since it is an announcement *about* an upcoming event where presentations will be given, and it details the content to be presented to investors, it is most closely related to the Investor Presentation (IP) category, which covers detailed presentations for investors. However, given the context of a formal meeting announcement, it could also be seen as a general regulatory announcement (RNS) or a specific type of AGM-related material if the meeting served that function, but the description points strongly to an investor briefing. Since the event itself is a 'Capital Markets Meeting' featuring presentations, 'Investor Presentation' (IP) is the most fitting classification for the *content* being delivered, even though this specific document is the *announcement* of that event. Given the options, and recognizing that Capital Markets Meetings often serve the function of an investor presentation, IP is selected. If the document were only announcing the *publication* of a report, RPA would be chosen, but this announces a live event featuring presentations.
2017-09-14 English
Arix to present at Rodman & Renshaw conference
Regulatory Filings Classification · 1% confidence The document is an RNS announcement (indicated by 'RNS Number : 2806Q' and 'This information is provided by RNS') detailing the company's participation and presentation schedule at an external investment conference ('19th Annual Rodman & Renshaw Global Investment Conference'). This is not a formal regulatory report (like 10-K or IR), nor is it a dividend announcement, earnings release, or management change. It is an announcement about an upcoming investor event where the company will present business overviews. This fits best under the general category for regulatory announcements that don't fit specific financial reporting types, or potentially Investor Presentation (IP) if it were the presentation itself. Since this is an announcement *about* participation in a conference where they will present, and it is filed via RNS, it is classified as a general Regulatory Filing (RNS), as it is an informational update to the market via the official channel.
2017-09-08 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.